Also known as: late-stage pancreatic cancer
Pancreatic cancer is a highly lethal malignancy, most commonly pancreatic ductal adenocarcinoma, often diagnosed late because early symptoms are nonspecific.
The FDA approved Novocure’s Optune Pax, a wearable tumor-treating fields device, for pancreatic cancer in combination with chemotherapy. Phase III PANOVA-3 data showed delayed pain progression and improved one-year overall survival in inoperable locally advanced disease.
Researchers identify DPY30 as an epigenetic target to sensitize pancreatic tumors to immunotherapy. UC San Diego researchers redirect CMV immunity against pancreatic cancer in preclinical models. A Fred Hutch researcher receives ACS grant to study immunotherapy resistance in melanoma.
EMA has initiated a rolling review of OS Therapies' OST-HER2 for preventing recurrence in fully resected pulmonary metastatic osteosarcoma. A potential conditional marketing authorization decision is expected in Q4 2026, with a confirmatory Phase 3 trial planned for Q3 2026 in Australia.
mRNA cancer vaccines showed promising pancreatic cancer trial results and boosted tumor-fighting drugs in other research. U.S. officials canceled $500 million in vaccine funding, while the NCI is backing a $200 million cancer vaccine partnership.
PARP inhibitors remain strongest in BRCA1/2-altered tumors as use beyond that group has been uneven. In June 2025, the FDA narrowed Zejula’s first-line ovarian maintenance indication to HRD-positive tumors only.
Wafik S. El-Deiry highlighted p53 research and the August 2025 approval of dordaviprone/modeyso, the first treatment for diffuse gliomas with H3K27M mutations. Separate posts also described glioblastoma precision oncology discussions and a lifetime achievement award in Mumbai.
BridgeBio Oncology Therapeutics said Bbo-11818 received FDA Fast Track designation for adult patients with advanced KRAS-mutated pancreatic ductal adenocarcinoma. The status may accelerate development and review and allow more frequent FDA communication during clinical trials.
Updated phase I data showed zoldonrasib produced a 52% confirmed objective response rate and 93% disease control rate in previously treated KRAS G12D-mutant NSCLC. No grade 4 or higher treatment-related adverse events were observed at the recommended phase II dose.
UAB researchers are advancing cancer prevention, tumor targeting and precision ablation, while AdvanCell is developing targeted alpha therapy and a prostate cancer drug in Phase 1 trials. Both efforts focus on new treatment approaches and research infrastructure.
Revolution Medicines said daraxonrasib extended median survival to 13.2 months versus 6.7 months for chemotherapy in a phase 3 pancreatic cancer study. The company plans to seek FDA approval for the KRAS-targeting pill.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07597772 |
Preliminary Trial of SNA014 for Pancreatic Cancer |
RECRUITING | EARLY_PHASE1 |
| NCT07595835 |
CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT07592338 |
Agreement Between Large Language Model-Generated Treatment Recommendations With Guideline-Based and Tumor Board Decisions in Gastrointestinal Cancer |
COMPLETED | |
| NCT07591480 |
Barriers And Facilitators To Clinical Trial Enrollment: A Qualitative Study Of Pancreatic Cancer Patients |
NOT_YET_RECRUITING | |
| NCT07589569 |
An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07586813 |
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors |
RECRUITING | PHASE2 |
| NCT07574957 |
Prediction of Peritoneal Dissemination of Digestive Tumors Through the Study of Circulating Tumor DNA |
NOT_YET_RECRUITING | |
| NCT07573215 |
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma |
AVAILABLE | |
| NCT07563738 |
A 2-part Phase 1/2 Open-label Trial on ODM-212 |
RECRUITING | PHASE1/PHASE2 |
| NCT07562152 |
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma |
RECRUITING | PHASE3 |
